Anaphylaxis and Severe Disseminated Intravascular Coagulation Due to Remdesivir
-
- Fukushima Noriyasu
- Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Kamachi Kazuharu
- Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Sato Tomonori
- Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Ishii Keitaro
- Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Tomimasu Rika
- Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Miyahara Masaharu
- Internal Medicine, Karatsu Red Cross Hospital, Japan
抄録
<p>A 69-year-old woman suffering with multiple myeloma developed coronavirus disease 2019 (COVID-19). Shortly after administration of remdesivir, she presented with symptoms of facial flushing, wheezing, and hypoxemia. Subsequently, thrombocytopenia and hypofibrinogenemia rapidly manifested, leading to a diagnosis of enhanced fibrinolytic-type disseminated intravascular coagulopathy (DIC). This clinical presentation was considered an immediate hypersensitivity reaction with associated coagulation abnormalities induced by remdesivir. Although remdesivir is generally considered safe and efficacious in the treatment of COVID-19, physicians should remain vigilant regarding the potential for severe adverse events associated with this medication. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 63 (6), 873-876, 2024-03-15
一般社団法人 日本内科学会